ASCO: June 3, 2013 General Poster Session
8:00am-11:45am . . . Kevetrin's "Coming Out" Party presented by Dr. Shapiro!
Abstract #TPS2627
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.